UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature

Cancer cell, 2017-04, Vol.31 (4), p.501-515.e8

2017

Volltextzugriff (PDF)

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2351-2363

2017

Volltextzugriff (PDF)

Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release

The Journal of clinical investigation, 2018-07, Vol.128 (7), p.2927-2943

2018

Volltextzugriff (PDF)

Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis

The Journal of pharmacology and experimental therapeutics, 2021-12, Vol.379 (3), p.290-300

2021

Volltextzugriff (PDF)

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Cancer discovery, 2018-09, Vol.8 (9), p.1096-1111

2018

Volltextzugriff (PDF)

The Ligand-Dependent Interaction of Mineralocorticoid Receptor with Coactivator and Corepressor Peptides Suggests Multiple Activation Mechanisms

Molecular endocrinology (Baltimore, Md.), 2005-06, Vol.19 (6), p.1460-1473

2005

Volltextzugriff (PDF)

Metalloproteases and inhibitors in arthritic diseases

Best practice & research. Clinical rheumatology, 2001-12, Vol.15 (5), p.805-829

2001

Volltextzugriff (PDF)

The CTSA Pharmaceutical Assets Portal – a public–private partnership model for drug repositioning

Drug discovery today. Therapeutic strategies, 2011-01, Vol.8 (3), p.77-83

2011

Volltextzugriff (PDF)

First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2022-10, Vol.40 (5), p.1001-1010

2022

Volltextzugriff (PDF)

Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B085-B085

2018

Volltextzugriff (PDF)

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

Cancer chemotherapy and pharmacology, 2018-06, Vol.81 (6), p.1129-1141

2018

Volltextzugriff (PDF)

831 Targeting tumor oxidative metabolism to overcome hypoxia-induced immunotherapy resistance in prostate cancer

Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A868-A868

2022

Volltextzugriff (PDF)

Orally Active MMP-1 Sparing α-Tetrahydropyranyl and α-Piperidinyl Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy in Cancer, Arthritis, and Cardiovascular Disease

Journal of medicinal chemistry, 2010-09, Vol.53 (18), p.6653-6680

2010

Volltextzugriff (PDF)

Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT003-CT003

2017

Volltextzugriff (PDF)

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2508-2508

2017

Volltextzugriff (PDF)

Evaluation of 1-(2-deoxy-2-fluoro-1-d-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent

World journal of microbiology & biotechnology, 2014-11, Vol.30 (11), p.3003-3010

2014

Volltextzugriff (PDF)

Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4693-4693

2015

Volltextzugriff (PDF)

Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2506-2506

2015

Volltextzugriff (PDF)

Amino-terminal alanine functions in a calcium-specific process essential for membrane binding by prothrombin fragment 1

Biochemistry (Easton), 1988-06, Vol.27 (13), p.4939-4945

1988

Volltextzugriff (PDF)

Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor

Biochimica et biophysica acta, 2002-07, Vol.1598 (1), p.10-23

2002

Volltextzugriff (PDF)

Modulation of adjuvant-induced arthritis by dietary arachidonic acid in essential fatty acid-deficient rats

Lipids, 1997-09, Vol.32 (9), p.979-988

1997

Volltextzugriff (PDF)

Carbohydrate-linked asparagine-101 of prothrombin contains a metal ion protected acetylation site. Acetylation of this site causes loss of metal ion induced protein fluorescence change

Biochemistry (Easton), 1988-06, Vol.27 (13), p.4946-4952

1988

Volltextzugriff (PDF)

Molecular cloning and expression of human leukotriene-C4 synthase

Proceedings of the National Academy of Sciences - PNAS, 1994-10, Vol.91 (21), p.9745-9749

1994

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Englisch
(52)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Humans
(23)
Animals
(18)
Biological And Medical Sciences
(12)
Amino Acid Sequence
(10)
Biochemistry & Molecular Biology
(10)
Male
(10)
Fundamental And Applied Biological Sciences. Psychology
(9)
Molecular And Cellular Biology
(8)
Molecular Sequence Data
(8)
Protein Conformation
(8)
Blood Coagulation. Blood Cells
(7)
Cattle
(7)
Female
(7)
Pharmacology & Pharmacy
(7)
Cancer
(6)
Coagulation Factors
(6)
Mice
(6)
Oncology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release

Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

The Ligand-Dependent Interaction of Mineralocorticoid Receptor with Coactivator and Corepressor Peptides Suggests Multiple Activation Mechanisms

Metalloproteases and inhibitors in arthritic diseases

The CTSA Pharmaceutical Assets Portal – a public–private partnership model for drug repositioning

First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors

Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies

831 Targeting tumor oxidative metabolism to overcome hypoxia-induced immunotherapy resistance in prostate cancer

Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)

Orally Active MMP-1 Sparing α-Tetrahydropyranyl and α-Piperidinyl Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy in Cancer, Arthritis, and Cardiovascular Disease

Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study

Evaluation of 1-(2-deoxy-2-fluoro-1-d-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent

Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors

Amino-terminal alanine functions in a calcium-specific process essential for membrane binding by prothrombin fragment 1

Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor

Modulation of adjuvant-induced arthritis by dietary arachidonic acid in essential fatty acid-deficient rats

Carbohydrate-linked asparagine-101 of prothrombin contains a metal ion protected acetylation site. Acetylation of this site causes loss of metal ion induced protein fluorescence change

Molecular cloning and expression of human leukotriene-C4 synthase

Suchergebnisse filtern